Comparing 5-Year Survival Rates Before and After Re-stratification of Stage I-III Right-Sided Colon Cancer Patients by Establishing the Presence/Absence of Occult Tumor Cells and Lymph Node Metastases in the Different Levels of Surgical Dissection

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2022 Aug 29

PMID 36036877

Authors

G S Banipal

B V Stimec

S N Andersen

A E Faerden

B Edwin

J Baral

J M Nesgaard

J Saltyte Benth

D Ignjatovic

Affiliations

Soon will be listed here.

Abstract

Background: To establish the impact of re-stratification on the outcomes of patients (stage I-III right-sided colon cancer) based on the presence/absence of occult tumor cells (OTC) and/or metastatic lymph nodes in the different levels of surgical dissection.

Methods: Consecutive patients were drawn from a multicenter prospective trial. After surgery, the surgical specimen was divided into the D1/D2 and D3 volumes before being further analyzed separately. All lymph nodes were examined with cytokeratin CAM 5.2 immunohistochemically. Lymph nodes containing metastases and OTC (micrometastases; isolated tumor cells) were identified. Re-stratification was as follows: RS1, stages I/II, no OTC in D1/D2 and D3 volumes; RS2, stages I/II, OTC in D1/D2 and/or D3; RS3, stage III, lymph node metastases in D1/D2, with/without OTC in D3; RS4, stage III, lymph node metastases in D3, with/without OTC in D3.

Results: Eighty-seven patients (39 men, 68.4 + 9.9 years) were included. The standard stratified (SS) group contained the following: stages I/II (SS1) 57 patients; stage III (SS2) 30 patients. Re-stratified (RS) contained RS1 (38), RS2 (19), RS3 (24), and RS4 (6) patients. Lymph node ratio (OTC) RS2: 0.157 D1/D2; 0.035 D3 and 0.092 complete specimens. Lymph node ratio RS3: 0.113 D1/D2; complete specimen 0.056. Overall survival and disease-free survival were p = 0.875 and p = 0.049 for SS and p = 0.144 and p = 0.001 for RS groups, respectively.

Conclusion: This re-stratification identifies a patient group with poor prognosis (RS4). Removing this group from SS2 eliminates all the differences in survival between RS2 and RS3 groups. The level of dissection of the affected nodes may have an impact on survival.

Clinical Trial: "Safe Radical D3 Right Hemicolectomy for Cancer through Preoperative Biphasic Multi-Detector Computed Tomography (MDCT) Angiography" registered at http://clinicaltrials.gov/ct2/show/NCT01351714.

Citing Articles

Are Metastatic Central Lymph Nodes (D3 volume) in right-sided Colon Cancer a Sign of Systemic Disease? A sub-group Analysis of an Ongoing Multicenter Trial.

Banipal G, Stimec B, Andersen S, Edwin B, Nesgaard J, Saltyte Benth J Ann Surg. 2023; 279(4):648-656.

PMID: 37753647 PMC: 10922660. DOI: 10.1097/SLA.0000000000006099.

References

Nesgaard J, Stimec B, Bakka A, Edwin B, Ignjatovic D . Navigating the mesentery: a comparative pre- and per-operative visualization of the vascular anatomy. Colorectal Dis. 2015; 17(9):810-8. DOI: 10.1111/codi.13003. View

Lal N, Chan D, Ng M, Vermeulen L, Buczacki S . Primary tumour immune response and lymph node yields in colon cancer. Br J Cancer. 2022; 126(8):1178-1185. PMC: 9023574. DOI: 10.1038/s41416-022-01700-1. View

Ulintz P, Greenson J, Wu R, Fearon E, Hardiman K . Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res. 2017; 24(9):2214-2224. PMC: 5932232. DOI: 10.1158/1078-0432.CCR-17-1425. View

Liu S, Li L, Sun H, Chen B, Yu M, Zhong M . D3 Versus D2 Lymphadenectomy in Right Hemicolectomy: A Systematic Review and Meta-analysis. Surg Innov. 2022; 29(3):416-425. DOI: 10.1177/15533506211060230. View

Tarazona N, Gimeno-Valiente F, Gambardella V, Zuniga S, Rentero-Garrido P, Huerta M . Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019; 30(11):1804-1812. DOI: 10.1093/annonc/mdz390. View

Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S . Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis. 2008; 11(4):354-64. DOI: 10.1111/j.1463-1318.2008.01735.x. View

Yamada T, Matsuda A, Koizumi M, Shinji S, Takahashi G, Iwai T . Liquid Biopsy for the Management of Patients with Colorectal Cancer. Digestion. 2018; 99(1):39-45. DOI: 10.1159/000494411. View

Yamamoto H, Tomita N, Inomata M, Furuhata T, Miyake Y, Noura S . OSNA-Assisted Molecular Staging in Colorectal Cancer: A Prospective Multicenter Trial in Japan. Ann Surg Oncol. 2015; 23(2):391-6. DOI: 10.1245/s10434-015-4880-x. View

Sepulveda A, Hamilton S, Allegra C, Grody W, Cushman-Vokoun A, Funkhouser W . Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; 35(13):1453-1486. DOI: 10.1200/JCO.2016.71.9807. View

10.

Kataoka K, Beppu N, Shiozawa M, Ikeda M, Tomita N, Kobayashi H . Colorectal cancer treated by resection and extended lymphadenectomy: patterns of spread in left- and right-sided tumours. Br J Surg. 2020; 107(8):1070-1078. DOI: 10.1002/bjs.11517. View

11.

Sloothaak D, van der Linden R, van de Velde C, Bemelman W, Lips D, van der Linden J . Prognostic implications of occult nodal tumour cells in stage I and II colon cancer: The correlation between micrometastasis and disease recurrence. Eur J Surg Oncol. 2017; 43(8):1456-1462. DOI: 10.1016/j.ejso.2017.04.012. View

12.

Naxerova K, Reiter J, Brachtel E, Lennerz J, van de Wetering M, Rowan A . Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017; 357(6346):55-60. PMC: 5536201. DOI: 10.1126/science.aai8515. View

13.

Livadaru C, Moscalu M, Ghitun F, Huluta A, Terinte C, Ferariu D . Postoperative Quality Assessment Score Can Select Patients with High Risk for Locoregional Recurrence in Colon Cancer. Diagnostics (Basel). 2022; 12(2). PMC: 8871190. DOI: 10.3390/diagnostics12020363. View

14.

Augestad K, Bakaki P, Rose J, Crawshaw B, Lindsetmo R, Dorum L . Metastatic spread pattern after curative colorectal cancer surgery. A retrospective, longitudinal analysis. Cancer Epidemiol. 2015; 39(5):734-44. DOI: 10.1016/j.canep.2015.07.009. View

15.

Bork U, Grutzmann R, Rahbari N, Scholch S, Distler M, Reissfelder C . Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 2014; 20(30):10296-304. PMC: 4130837. DOI: 10.3748/wjg.v20.i30.10296. View

16.

Koyanagi K, Bilchik A, Saha S, Turner R, Wiese D, McCarter M . Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res. 2008; 14(22):7391-6. PMC: 2586882. DOI: 10.1158/1078-0432.CCR-08-0290. View

17.

Nesgaar J, Stimec B, Bakka A, Edwin B, Bergamaschi R, Ignjatovic D . Right Colectomy with Extended D3 Mesenterectomy: Anterior and Posterior to the Mesenteric Vessels. Surg Technol Int. 2019; 35:138-142. View

18.

Weiser M . AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018; 25(6):1454-1455. DOI: 10.1245/s10434-018-6462-1. View

19.

Murray N, Aedo S, Villalon R, Lopez M, Minzer S, Munoz L . Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse. Ecancermedicalscience. 2019; 13:935. PMC: 6605629. DOI: 10.3332/ecancer.2019.935. View

20.

Patriarca C, Pini G, Conti G . Invasion and metastasis: a historical perspective. Pathologica. 2021; 112(4):229-233. PMC: 8183350. DOI: 10.32074/1591-951X-111. View